Abstract: An intelligent control gas suction-type electric propulsion system applicable to multi-flow regimes: an ultra-low orbit rare gas is used as a working medium for attitude orbit control and resistance compensation propulsion, the gas is collected and inputted into an intelligent feedback pressurization system by means of a parabolic gas intake duct, intelligent feedback and pressurization are performed on the gas working medium by a molecular pump and a gas pump and the medium is stored in a working fluid storage tank so as to supply a hybrid thruster system that consists of seven sets of electric thrusters to generate thrust, which may achieve multiple thrust modes, and achieve the purpose of attitude orbit control and resistance compensation.

Abstract: An intelligent control gas suction-type electric propulsion system applicable to multi-flow regimes: an ultra-low orbit rare gas is used as a working medium for attitude orbit control and resistance compensation propulsion, the gas is collected and inputted into an intelligent feedback pressurization system by means of a parabolic gas intake duct, intelligent feedback and pressurization are performed on the gas working medium by a molecular pump and a gas pump and the medium is stored in a working fluid storage tank so as to supply a hybrid thruster system that consists of seven sets of electric thrusters to generate thrust, which may achieve multiple thrust modes, and achieve the purpose of attitude orbit control and resistance compensation.

Abstract: The present teachings provide compounds of formula I and their pharmaceutically acceptable salts, hydrates, and esters, wherein R1, R2, and X are as defined herein. The present teachings also provide methods of making the compounds of formula I, and methods of treating autoimmune and inflammatory diseases by administering a therapeutically effective amount of a compound or compounds of formula I to a mammal including a human.

Abstract: This invention provides a compound of Formula 1 where Ar, X, R1, R2, R3, and R4 are defined herein, or a pharmaceutically acceptable salt thereof useful in the prevention or inhibition of diseases associated with the Ras/Raf/MEK signaling cascade in a mammal, such as neoplasms, strokes, osteoporosis, cancer, rheumatoid arthritis, inflammatory disease, polycystic kidney disease, and colonic polyps, and methods of making the compounds of formula 1 and intermediates.

Abstract: This invention provides a compound of Formula 1 where Ar, X, R1, R2, R3, and R4 are defined herein, or a pharmaceutically acceptable salt thereof useful in the prevention or inhibition of diseases associated with the Ras/Raf/MEK signaling cascade in a mammal, such as neoplasms, strokes, osteoporosis, cancer, rheumatoid arthritis, inflammatory disease, polycystic kidney disease, and colonic polyps, and methods of making the compounds of formula 1 and intermediates.

Abstract: This invention relates to compounds having the structure of Formula I wherein R1, R2, R3, and R4 are described herein.

Abstract: This invention provides a compound of Formula 1 where Ar, X, R1, R2, R3, and R4 are defined herein, or a pharmaceutically acceptable salt thereof useful in the prevention or inhibition of diseases associated with the Ras/Raf/MEK signaling cascade in a mammal, such as neoplasms, strokes, osteoporosis, cancer, rheumatoid arthritis, inflammatory disease, polycystic kidney disease, and colonic polyps, and methods of making the compounds of formula 1 and intermediates.

Abstract: A process for the preparation of 4-hydroxythieno[2,3-b]pyridine-5-carbonitriles, which can be useful for the preparation of protein kinase inhibitors, is provided.

Abstract: This invention provides compounds of Formula (1a)-(1f), II wherein: X, m, n, q, R1, R2, R3, R4, R5, R6, R7, R8, R9, Y, Q, Z, Z?, Z??, Z? and J are defined hereinbefore in the specification, which are useful in the treatment of cancer, stroke, myocardial infarction, neuropathic pain, osteoporosis, polycystic kidney disease, autoimmune disease, rheumatoid arthritis, and transplant rejection and process for producing said compounds.

Abstract: The present teachings provide compounds of formula I and their pharmaceutically acceptable salts, hydrates, and esters, wherein R1, R2, and X are as defined herein. The present teachings also provide methods of making the compounds of formula I, and methods of treating autoimmune and inflammatory diseases by administering a therapeutically effective amount of a compound or compounds of formula I to a mammal including a human.

Abstract: This invention provides compounds of Formula (1a)–(1f), II wherein: X, m, n, q, R1, R2, R3, R4, R5, R6, R7, R8, R9, Y, Q, Z, Z?, Z??, Z? and J are defined hereinbefore in the specification, which are useful in the treatment of cancer, stroke, myocardial infarction, neuropathic pain, osteoporosis, polycystic kidney disease, autoimmune disease, rheumatoid arthritis, and transplant rejection and process for producing said compounds.

Abstract: Disclosed are compounds of Formula I: wherein R1, R2, R3, R4, and X, are defined hereinbefore in the specification, which can be useful in the treatment of autoimmune and inflammatory diseases, and processes for producing said compounds.

Abstract: This invention provides compounds of formula 1, having the structure which are useful as inhibitors of protein tyrosine kinase and are antiproliferative agents.

Abstract: This invention provides compounds of formula 1, having the structure which are useful as inhibitors of protein tyrosine kinase and are antiproliferative agents.

Abstract: This invention relates to novel methods of use of certain pyrazolo[1,5-a]pyrimidine compounds and the therapeutically acceptable salts thereof. This invention also relates to novel methods of using these compounds as anti-proliferative agents in mammals, including humans.

Abstract: This invention relates to compounds having the structure of Formula I wherein R1, R2, R3, and R4 are described herein.

Abstract: This invention provides compounds of Formula (1a)-(1f) wherein: X, R1, and R2 are defined hereinbefore in the specification, which are useful in the treatment of cancer, stroke, osteoporosis, polycystic kidney disease, autoimmune disease, rheumatoid arthritis, and transplant rejection and process for producing said compounds.

Abstract: This invention provides a compound of Formula 1 where Ar, X, R1, R2, R3, and R4 are defined herein, or a pharmaceutically acceptable salt thereof useful in the prevention or inhibition of diseases associated with the Ras/Raf/MEK signaling cascade in a mammal, such as neoplasms, strokes, osteoporosis, cancer, rheumatoid arthritis, inflammatory disease, polycystic kidney disease, and colonic polyps, and methods of making the compounds of formula 1 and intermediates.

Abstract: This invention provides compounds of Formula (1a)-(1f), II 1

Abstract: This invention provides compounds of Formula (I), having the structure 1